Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. develops precision oncology therapies for cancers driven by the RAS/MAPK pathway. News on ERAS commonly centers on its RAS-targeting pipeline, including ERAS-0015, an investigational oral pan-RAS molecular glue evaluated in RAS-mutant solid tumors, and ERAS-4001, an oral pan-KRAS inhibitor for KRAS-mutant solid tumors.
Company updates frequently cover Phase 1 clinical data, dose-escalation results, trial collaborations and supply agreements, intellectual-property protection, development rights, public offering activity, financial results, and healthcare conference presentations. Recurring cancer settings in company disclosures include non-small cell lung cancer, pancreatic adenocarcinoma, colorectal cancer, and other RAS-mutant solid tumors.
Summary not available.
Erasca, Inc. (Nasdaq: ERAS) announced the dosing of the first patient in the HERKULES-3 trial, a Phase 1b/2 clinical study evaluating ERAS-007, an ERK1/2 inhibitor, in combination with various agents for treating colorectal cancer (CRC). The trial aims to address mutations in BRAF, KRAS, and NRAS, impacting over half of CRC patients. Current therapies show limited effectiveness, with many patients experiencing rapid disease progression. HERKULES-3 will explore the safety and effectiveness of these combinations, potentially leading to significant advancements in CRC treatment.
ERAS-007, a leading ERK1/2 inhibitor, has entered Phase 1b/2 HERKULES-2 trial, focusing on advanced non-small cell lung cancer (NSCLC). Erasca, Inc. has initiated patient dosing to evaluate ERAS-007's effectiveness in combination with osimertinib. This trial aims to address unmet needs, especially for patients resistant to current therapies. The broad applicability of ERAS-007 was reinforced by recent preclinical findings showing strong anti-tumor activity, particularly in tumors with specific mutations. Future expansions will explore additional combinations across various cancer types.
Erasca, Inc. (Nasdaq: ERAS) announced a clinical trial collaboration with Pfizer to evaluate ERAS-007, an ERK1/2 inhibitor, in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer. The HERKULES-3 Phase 1b/2 trial is set to start in H2 2021. The collaboration aims to address the challenge of resistance observed in existing treatments. With about 1.8 million CRC cases globally and 10% related to BRAF V600E mutations, this trial could significantly impact patient outcomes.
San Diego-based Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced participation in the Morgan Stanley 19th Annual Global Healthcare Conference. The event features a fireside chat with CEO Jonathan E. Lim and CFO David M. Chacko on September 10, 2021, at 4:15 PM ET. The live webcast can be accessed on the company’s website, with an archived replay available for 30 days post-event. Erasca focuses on developing therapies for RAS/MAPK pathway-driven cancers, aiming to erase cancer through innovative treatments.
Erasca, Inc. (Nasdaq: ERAS) reported its financial results for Q2 2021, revealing a net loss of $28.2 million, or $(1.20) per share, compared to a loss of $5.5 million in Q2 2020. The company successfully closed a $345 million IPO, enhancing its cash position to $198.7 million. Erasca initiated its HERKULES-1 clinical trial for ERAS-007 and nominated ERAS-3490 as a development candidate, both pivotal for targeting RAS/MAPK pathway-driven cancers. The company expects its cash reserves to fund operations for at least the next 24 months.
Erasca, Inc. (Nasdaq: ERAS) announced the closing of its initial public offering on July 20, 2021, raising $345 million by selling 21,562,500 shares at $16.00 each. This includes the underwriters' full exercise of an option for 2,812,500 additional shares. J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI, and Guggenheim Securities were the joint book-running managers. The registration statement for the offering became effective on July 15, 2021. Erasca focuses on therapies targeting RAS/MAPK pathway-driven cancers, positioning itself as a leader in precision oncology.
Erasca, Inc. (Nasdaq: ERAS) has priced its upsized initial public offering at $16.00 per share for 18,750,000 shares, aiming for gross proceeds of $300.0 million. The shares are set to trade on Nasdaq starting July 16, 2021, with the offering closing on July 20, 2021, contingent on customary conditions. Underwriters have the option to purchase an additional 2,812,500 shares within 30 days. Erasca, focused on therapies for RAS/MAPK pathway-driven cancers, aims to leverage the funds for further development of its pipeline.